GlaxoSmithKline's (GSK) Advair HFA Inhalation Aerosol is Now Available
More News related to GSK
- Piper Jaffray Downgrades Phase Forward (PFWD) to Neutral; Lack of Near-Term Catalysts
- Phase Forward (PFWD) Signs Multi-Yr, Multi-Million Dollar Contract with GlaxoSmithKline (GSK)
- Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018
- Society of Hispanic Professional Engineers Elects New National Board With Raytheon's Manny Hernandez as President
- Morning Movers 6/17: MERX, CYTR, SVNT, MIPI, TSTR Higher; ETFC, CTIC, AIB Lower
Advair HFA Inhalation Aerosol, a new formulation combining fluticasone propionate and salmeterol in a metered-dose inhaler (MDI) delivery device, is now available in pharmacies nationwide. Advair, a medicine used in the treatment of asthma, became available in 2001 as a dry-powdered inhaler known as Advair Diskus.
Advair HFA was developed and is marketed by GlaxoSmithKline (NYSE: GSK), a research-based pharmaceutical and a world leader in respiratory care. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Related Categories
Corporate NewsStocks Mentioned
-7.34Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
